This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2013 Jul;24(7):1717-1720.

doi: 10.1093/annonc/mdt234.

Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore

A Goldkorn¹, A M Aparicio², D I Quinn³

Affiliations

Affiliations

¹ Developmental Therapeutics and Genitourinary Cancer Programs, University of Southern California Norris Comprehensive Cancer Center, Los Angeles.
² Department of Genitourinary Oncology, M. D. Anderson Cancer Center, Houston, USA.
³ Developmental Therapeutics and Genitourinary Cancer Programs, University of Southern California Norris Comprehensive Cancer Center, Los Angeles;. Electronic address: diquinn@med.usc.edu.

PMID: 23798673
DOI: 10.1093/annonc/mdt234

Free article

Editorial

Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore

A Goldkorn et al. Ann Oncol. 2013 Jul.

Free article

. 2013 Jul;24(7):1717-1720.

doi: 10.1093/annonc/mdt234.

Authors

A Goldkorn¹, A M Aparicio², D I Quinn³

Affiliations

¹ Developmental Therapeutics and Genitourinary Cancer Programs, University of Southern California Norris Comprehensive Cancer Center, Los Angeles.
² Department of Genitourinary Oncology, M. D. Anderson Cancer Center, Houston, USA.
³ Developmental Therapeutics and Genitourinary Cancer Programs, University of Southern California Norris Comprehensive Cancer Center, Los Angeles;. Electronic address: diquinn@med.usc.edu.

PMID: 23798673
DOI: 10.1093/annonc/mdt234

No abstract available

PubMed Disclaimer

Comment on

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C. Loriot Y, et al. Ann Oncol. 2013 Jul;24(7):1807-1812. doi: 10.1093/annonc/mdt136. Epub 2013 Apr 10. Ann Oncol. 2013. PMID: 23576708
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Noonan KL, et al. Ann Oncol. 2013 Jul;24(7):1802-1807. doi: 10.1093/annonc/mdt138. Epub 2013 Apr 12. Ann Oncol. 2013. PMID: 23585511

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal